The price-to-earnings ratio for CytomX Therapeutics Inc (NASDAQ: CTMX) is above average at 2.36x. The 36-month beta value for CTMX is also noteworthy at 1.17. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for CTMX is 78.64M, and at present, short sellers hold a 12.39% of that float. The average trading volume of CTMX on May 12, 2025 was 2.13M shares.
CTMX) stock’s latest price update
CytomX Therapeutics Inc (NASDAQ: CTMX)’s stock price has gone decline by -14.83 in comparison to its previous close of 1.09, however, the company has experienced a 15.76% increase in its stock price over the last five trading days. globenewswire.com reported 2025-05-05 that SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Monday, May 12, 2025, before the open of the U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT.
CTMX’s Market Performance
CytomX Therapeutics Inc (CTMX) has experienced a 15.76% rise in stock performance for the past week, with a 85.57% rise in the past month, and a 10.52% rise in the past quarter. The volatility ratio for the week is 21.32%, and the volatility levels for the past 30 days are at 13.46% for CTMX. The simple moving average for the last 20 days is 21.22% for CTMX’s stock, with a simple moving average of -4.31% for the last 200 days.
Analysts’ Opinion of CTMX
Many brokerage firms have already submitted their reports for CTMX stocks, with Piper Sandler repeating the rating for CTMX by listing it as a “Overweight.” The predicted price for CTMX in the upcoming period, according to Piper Sandler is $2.50 based on the research report published on April 14, 2025 of the current year 2025.
Piper Sandler, on the other hand, stated in their research note that they expect to see CTMX reach a price target of $3.50, previously predicting the price at $2.25. The rating they have provided for CTMX stocks is “Overweight” according to the report published on May 28th, 2024.
Wedbush gave a rating of “Outperform” to CTMX, setting the target price at $8 in the report published on May 09th of the previous year.
CTMX Trading at 39.02% from the 50-Day Moving Average
After a stumble in the market that brought CTMX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.96% of loss for the given period.
Volatility was left at 13.46%, however, over the last 30 days, the volatility rate increased by 21.32%, as shares surge +87.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +37.50% upper at present.
During the last 5 trading sessions, CTMX rose by +15.76%, which changed the moving average for the period of 200-days by -35.53% in comparison to the 20-day moving average, which settled at $0.7660. In addition, CytomX Therapeutics Inc saw -9.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CTMX starting from McCarthy Sean A., who sale 37,656 shares at the price of $0.60 back on Mar 18 ’25. After this action, McCarthy Sean A. now owns 995,195 shares of CytomX Therapeutics Inc, valued at $22,556 using the latest closing price.
Ogden Christopher, the Chief Financial Officer of CytomX Therapeutics Inc, sale 8,551 shares at $0.60 during a trade that took place back on Mar 18 ’25, which means that Ogden Christopher is holding 201,026 shares at $5,122 based on the most recent closing price.
Stock Fundamentals for CTMX
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.99 for the gross margin
The net margin for CytomX Therapeutics Inc stands at 0.23. The total capital return value is set at 0.72.
Based on CytomX Therapeutics Inc (CTMX), the company’s capital structure generated 1.05 points at debt to capital in total, while cash flow to debt ratio is standing at -9.19.
Currently, EBITDA for the company is 25.0 million with net debt to EBITDA at -1.09. When we switch over and look at the enterprise to sales, we see a ratio of 0.33. The receivables turnover for the company is 44.51for trailing twelve months and the total asset turnover is 1.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.25.
Conclusion
In summary, CytomX Therapeutics Inc (CTMX) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
